About Sionna Therapeutics, Inc.
https://www.sionnatx.comSionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
CEO
Michael Cloonan
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 84
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:10.45M
Value:$430.14M
TPG GP A, LLC
Shares:6.74M
Value:$277.76M
ORBIMED ADVISORS LLC
Shares:3.7M
Value:$152.57M
Summary
Showing Top 3 of 79
About Sionna Therapeutics, Inc.
https://www.sionnatx.comSionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $23.7M ▲ | $-20.28M ▼ | 0% | $-0.46 ▼ | $-20.18M ▼ |
| Q2-2025 | $0 | $21.76M ▲ | $-18.07M ▼ | 0% | $-0.41 ▼ | $-17.92M ▲ |
| Q1-2025 | $0 | $19.66M ▲ | $-16.48M ▼ | 0% | $-0.37 ▼ | $-19.23M ▼ |
| Q4-2024 | $0 | $18.13M ▲ | $-15.85M ▼ | 0% | $-0.36 ▼ | $-17.97M ▼ |
| Q2-2024 | $0 | $11.13M | $-8.55M | 0% | $-0.19 | $-8.39M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $248.33M ▼ | $339.27M ▼ | $17.6M ▲ | $321.67M ▼ |
| Q2-2025 | $262.57M ▼ | $352.05M ▼ | $15.62M ▼ | $336.43M ▼ |
| Q1-2025 | $269.67M ▲ | $369.67M ▲ | $17.91M ▼ | $351.77M ▲ |
| Q4-2024 | $147.54M ▲ | $185.75M ▼ | $349.46M ▲ | $-163.71M ▼ |
| Q3-2024 | $137.47M | $197.26M | $345.81M | $-148.55M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-20.28M ▼ | $-15.23M ▲ | $23.1M ▲ | $1.97M ▲ | $9.85M ▲ | $-15.32M ▲ |
| Q2-2025 | $-18.07M ▼ | $-18.15M ▼ | $-23.25M ▲ | $-312K ▼ | $-41.71M ▼ | $-18.15M ▼ |
| Q1-2025 | $-16.48M ▼ | $-16.29M ▼ | $-141.19M ▼ | $202.39M ▲ | $44.91M ▲ | $-16.37M ▼ |
| Q4-2024 | $-15.85M ▼ | $-11.78M ▼ | $15.23M ▲ | $-1.41M ▼ | $2.04M ▲ | $-11.81M ▼ |
| Q2-2024 | $-8.55M | $-10.14M | $-28.62M | $38K | $-38.73M | $-10.14M |
CEO
Michael Cloonan
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 84
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
RA CAPITAL MANAGEMENT, L.P.
Shares:10.45M
Value:$430.14M
TPG GP A, LLC
Shares:6.74M
Value:$277.76M
ORBIMED ADVISORS LLC
Shares:3.7M
Value:$152.57M
Summary
Showing Top 3 of 79